Expedited Pathways Comparisons - US EU CHN
This presentation from Parexel's virtual roundtable, entitled "Making expedited regulatory pathways work for global drug development programs" outlines regional comparisons of expedited pathways in US, EU and China.
Related Insights
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Related Insights
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021